J&J Raises Earnings Outlook After Jump in Quarterly Drug Sales
Guidance·2 articles across 2 outlets
Story updated Rewritten when the story materially grows; the wire is checked every 15 minutesAbout this data
Johnson & Johnson raised its profit guidance as demand for newer drugs in cancer and autoimmune diseases overshadowed more anemic growth in the company’s medical device business.
The increase in earnings outlook reflects the strong performance of its pharmaceutical segment, which has been a key driver for the company amidst challenges in other areas.
Johnson & Johnson
Sources
Every quote below is verbatim from the article it is attributed to.
SourceReports the news
“Johnson & Johnson raised its profit guidance as demand for newer drugs in cancer and autoimmune diseases overshadowed more anemic growth in the company’s medical device business.”
Bloomberg — J&J Lifts Earnings Outlook After Jump in Quarterly Drug Sales